Suhler Eric B, Martin Tammy M, Rosenbaum James T
Casey Eye Institute, Oregon Health & Science University, and Portland VA Medical Center, Ophthalmology Service, 97239, USA.
Curr Opin Ophthalmol. 2003 Dec;14(6):378-83. doi: 10.1097/00055735-200312000-00010.
To review current knowledge about the pathogenesis, clinical presentation, and treatment of HLA-B27-associated uveitis, which is the most commonly identified cause of uveitis in community-based practice and an important cause of ocular morbidity.
Significant advances have been made in understanding the pathogenesis of HLA-B27-associated ocular and systemic disease, especially with regard to the genetic underpinning of these diseases. Increasing attention has also been focused on the use of alternative therapies in the treatment of HLA-B27-associated uveitis, with special attention to sulfa class antibiotics, historically have been used to treat the articular manifestations of the spondyloarthritides, and newer drugs that inhibit tumor necrosis factor-alpha.
The next several years promise to yield exciting new advances in understanding of the genetic epidemiology and treatment of HLA-B27-associated uveitis.
回顾目前关于HLA - B27相关性葡萄膜炎的发病机制、临床表现和治疗的知识，HLA - B27相关性葡萄膜炎是社区实践中最常见的葡萄膜炎病因，也是眼部发病的重要原因。
在理解HLA - B27相关性眼部和全身疾病的发病机制方面取得了重大进展，特别是在这些疾病的遗传基础方面。人们也越来越关注在HLA - B27相关性葡萄膜炎治疗中使用替代疗法，特别关注磺胺类抗生素，其历史上一直用于治疗脊柱关节炎的关节表现，以及抑制肿瘤坏死因子-α的新药。
未来几年有望在HLA - B27相关性葡萄膜炎的遗传流行病学和治疗方面取得令人兴奋的新进展。
